The ulcerative colitis (UC) therapy market is expected to grow steadily over the next decade. The entry of first-in-UC oral therapies (e.g., Pfizer’s Xeljanz / Xeljanz XR) for moderate to severe disease, together with emerging agents with novel MOAs and a general increase in the use of targeted therapies, will drive market growth. In particular, the availability of non-TNF biologics (e.g., Takeda’s Entyvio, Janssen’s Stelara) and the oral Jak inhibitor Xeljanz / Xeljanz XR will expand physicians’ treatment armamentarium and intensify market competition. Offsetting this growth will be the continued generic erosion of conventional agents and the entry of and increased physician comfort prescribing less-expensive biosimilars, factors that will pose hurdles to the uptake of emerging therapies.
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.